David Lebowitz
Stock Analyst at Citigroup
(2.30)
# 1,459
Out of 4,667 analysts
97
Total ratings
41.86%
Success rate
-4.55%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $65 → $68 | $43.01 | +58.10% | 4 | Nov 13, 2024 | |
| INCY Incyte | Maintains: Buy | $92 → $97 | $70.80 | +37.01% | 4 | Oct 30, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $25 → $19 | $14.13 | +34.47% | 6 | Oct 25, 2024 | |
| CLDX Celldex Therapeutics | Initiates: Buy | $70 | $27.01 | +159.16% | 1 | Oct 7, 2024 | |
| COGT Cogent Biosciences | Maintains: Buy | $13 → $15 | $9.24 | +62.34% | 3 | Sep 24, 2024 | |
| ASND Ascendis Pharma | Maintains: Buy | $178 → $207 | $123.92 | +67.04% | 12 | Sep 17, 2024 | |
| PTCT PTC Therapeutics | Maintains: Sell | $18 → $26 | $42.60 | -38.96% | 2 | May 21, 2024 | |
| PLRX Pliant Therapeutics | Maintains: Buy | $45 → $44 | $12.93 | +240.29% | 4 | May 7, 2024 | |
| BPMC Blueprint Medicines | Maintains: Sell | $65 → $76 | $96.32 | -21.10% | 5 | May 3, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $39 → $37 | $19.40 | +90.72% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $321.03 | +18.99% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $46 | $23.52 | +95.58% | 2 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $34.79 | -10.89% | 1 | Dec 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 → $60 | $35.01 | +71.38% | 11 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $62.61 | +53.33% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $2.14 | +460.75% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $249.86 | -34.36% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $10.33 | +277.54% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $15.80 | +32.95% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $27 | $0.77 | +3,405.58% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $3.45 | +306.39% | 2 | Oct 12, 2021 |
Mirum Pharmaceuticals
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $43.01
Upside: +58.10%
Incyte
Oct 30, 2024
Maintains: Buy
Price Target: $92 → $97
Current: $70.80
Upside: +37.01%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $25 → $19
Current: $14.13
Upside: +34.47%
Celldex Therapeutics
Oct 7, 2024
Initiates: Buy
Price Target: $70
Current: $27.01
Upside: +159.16%
Cogent Biosciences
Sep 24, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $9.24
Upside: +62.34%
Ascendis Pharma
Sep 17, 2024
Maintains: Buy
Price Target: $178 → $207
Current: $123.92
Upside: +67.04%
PTC Therapeutics
May 21, 2024
Maintains: Sell
Price Target: $18 → $26
Current: $42.60
Upside: -38.96%
Pliant Therapeutics
May 7, 2024
Maintains: Buy
Price Target: $45 → $44
Current: $12.93
Upside: +240.29%
Blueprint Medicines
May 3, 2024
Maintains: Sell
Price Target: $65 → $76
Current: $96.32
Upside: -21.10%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $39 → $37
Current: $19.40
Upside: +90.72%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $321.03
Upside: +18.99%
Feb 23, 2024
Maintains: Buy
Price Target: $42 → $46
Current: $23.52
Upside: +95.58%
Dec 15, 2023
Initiates: Buy
Price Target: $31
Current: $34.79
Upside: -10.89%
Jul 31, 2023
Upgrades: Buy
Price Target: $36 → $60
Current: $35.01
Upside: +71.38%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $62.61
Upside: +53.33%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $2.14
Upside: +460.75%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $249.86
Upside: -34.36%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $10.33
Upside: +277.54%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $15.80
Upside: +32.95%
Oct 12, 2021
Maintains: Overweight
Price Target: $29 → $27
Current: $0.77
Upside: +3,405.58%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $3.45
Upside: +306.39%